{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:53:36Z","timestamp":1770274416226,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Loop diuretics are used to manage fluid retention in patients with end-stage kidney disease undergoing hemodialysis (HD). This randomized, double-blind, placebo-controlled, Phase 2 trial evaluated the efficacy and safety of tolvaptan, a vasopressin V2 receptor antagonist, in Japanese HD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 124 patients (24-h urine volume \u2265500\u2009mL) on thrice-weekly HD were randomized to receive oral tolvaptan 15\u2009mg\/day (n\u2009=\u200940), tolvaptan 30\u2009mg\/day (n\u2009=\u200940) or placebo (n\u2009=\u200944) for 24\u2009weeks. Efficacy endpoints were change from baseline in 24-h urine volume, total fluid removal by HD per week and interdialytic weight gain (IDWG). Safety was assessed via the incidence of treatment-emergent adverse events (TEAEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At treatment end, the difference (95% confidence interval) from the placebo group in the mean change from baseline in 24-h urine volume was significant in the tolvaptan 15\u2009mg {429.1\u2009mL [95% confidence interval (CI) 231.0, 627.2]; P\u2009&amp;lt;\u20090.0001} and 30\u2009mg [371.6\u2009mL (95% CI 144.1, 599.2); P\u2009=\u20090.0017] groups. The mean changes from baseline in total fluid removal by HD and IDWG were not significantly different in the tolvaptan groups versus the placebo group. Although the proportion of patients with TEAEs was lower in the placebo group (77.3%) than in the tolvaptan groups (92.3%), tolvaptan was safe and well-tolerated during the study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tolvaptan significantly sustained diuretic action for 24\u2009weeks in HD patients but did not reduce total fluid removal by HD per week and IDWG to the same extent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa148","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:16:48Z","timestamp":1589631408000},"page":"1088-1097","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-5575","authenticated-orcid":false,"given":"Hiroaki","family":"Ogata","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Shimofurutani","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Okada","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Nagamoto","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"2021052808593196600_gfaa148-B1","first-page":"219","article-title":"Study of hemodialysis without water removal for retention of residual renal function [in Japanese]","volume":"63","author":"Kurihara","year":"2007","journal-title":"Kidney Dial"},{"key":"2021052808593196600_gfaa148-B2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11255-012-0346-2","article-title":"Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study","volume":"46","author":"Liu","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"2021052808593196600_gfaa148-B3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.ajkd.2006.12.012","article-title":"Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)","volume":"49","author":"Bragg-Gresham","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2021052808593196600_gfaa148-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","article-title":"Loop diuretics in clinical practice","volume":"13","author":"Oh","year":"2015","journal-title":"Electrolyte Blood Press"},{"key":"2021052808593196600_gfaa148-B5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrneph.2011.175","article-title":"Diuretic use in renal disease","volume":"8","author":"Sica","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2021052808593196600_gfaa148-B6","first-page":"756","article-title":"Analysis of case reports of tolvaptan administered patients (learning indication of tolvaptan from 9 cases of chronic kidney disease) [in Japanese]","volume":"48","author":"Mori","year":"2012","journal-title":"Med Drug J"},{"key":"2021052808593196600_gfaa148-B7","first-page":"860","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2021052808593196600_gfaa148-B8","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"2021052808593196600_gfaa148-B9","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25(Suppl 1","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2021052808593196600_gfaa148-B10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol Res"},{"key":"2021052808593196600_gfaa148-B11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2021052808593196600_gfaa148-B12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","article-title":"The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial","volume":"19","author":"Muto","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2021052808593196600_gfaa148-B13","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2021052808593196600_gfaa148-B14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3747\/pdi.2013.00290","article-title":"A pilot study examining the effects of tolvaptan on residual renal function in peritoneal dialysis for diabetics","volume":"35","author":"Hiramatsu","year":"2015","journal-title":"Perit Dial Int"},{"key":"2021052808593196600_gfaa148-B15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ndt\/gfh650","article-title":"A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension","volume":"20","author":"Dussol","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2021052808593196600_gfaa148-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199100413-00003","article-title":"How do loop diuretics act?","volume":"41(Suppl 3","author":"Wittner","year":"1991","journal-title":"Drugs"},{"key":"2021052808593196600_gfaa148-B17","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021052808593196600_gfaa148-B18","doi-asserted-by":"crossref","first-page":"F1115","DOI":"10.1152\/ajprenal.00337.2002","article-title":"Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure","volume":"284","author":"Chen","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021052808593196600_gfaa148-B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"key":"2021052808593196600_gfaa148-B20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1525-139X.2011.00968.x","article-title":"Emerging importance of residual renal function in end-stage renal failure","volume":"24","author":"Vilar","year":"2011","journal-title":"Semin Dial"},{"key":"2021052808593196600_gfaa148-B21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.kint.2016.02.037","article-title":"Preservation of residual kidney function in hemodialysis patients: reviving an old concept","volume":"90","author":"Mathew","year":"2016","journal-title":"Kidney Int"},{"key":"2021052808593196600_gfaa148-B22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ki.2010.383","article-title":"Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality","volume":"79","author":"Flythe","year":"2011","journal-title":"Kidney Int"},{"key":"2021052808593196600_gfaa148-B23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","article-title":"Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure","volume":"21","author":"Katsumata","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"2021052808593196600_gfaa148-B24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","article-title":"Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease","volume":"81","author":"Uemura","year":"2017","journal-title":"Circ J"},{"key":"2021052808593196600_gfaa148-B25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/6\/1088\/38276703\/gfaa148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/6\/1088\/38276703\/gfaa148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T09:24:09Z","timestamp":1622193849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/6\/1088\/5903094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,9]]},"published-print":{"date-parts":[[2021,5,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa148","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,9,9]]}}}